PharmiWeb.com - Global Pharma News & Resources

Pharmaco - Press Releases

Date Title Company
24-Feb-2025 ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease Sanofi
24-Feb-2025 Infection prevention in motion TENTE International GmbH
24-Feb-2025 Original-Research: Formycon AG (von First Berlin Equity Research GmbH) Formycon AG
21-Feb-2025 MSF encourages parents to participate in ongoing vaccination campaign in collaboration with Sokoto state government Médecins Sans Frontières
21-Feb-2025 Microbiotica unveils data on the mechanism of action of MB310, a clinical-stage drug candidate in development for the treatment of ulcerative colitis Microbiotica
21-Feb-2025 Infection prevention in motion TENTE International GmbH
21-Feb-2025 Boehringer Ingelheim and partners start clinical development of a first-in-class, inhaled gene therapy for people with cystic fibrosis Boehringer Ingelheim
21-Feb-2025 Gilead’s Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis Gilead
21-Feb-2025 Alcon Announces U.S. Launch of Voyager DSLT, First-of-its-Kind Treatment for Glaucoma and Ocular Hypertension Alcon
21-Feb-2025 Danaher Announces Appointment of Charles Lamanna to Danaher Board Danaher
21-Feb-2025 Eleva Appoints Martin Bauer, MD as Chief Medical Officer Adding Substantial Clinical Development Expertise to the Organization Eleva
21-Feb-2025 Termination of proposed combination with HOOKIPA Pharma Inc. Poolbeg Pharma plc
21-Feb-2025 Celltrion Unveils New Post-Hoc Analyses of LIBERTY Studies at the 20th ECCO Congress Further Evaluating the Efficacy and Safety of Subcutaneous (SC) Infliximab Celltrion
21-Feb-2025 PharmaBlock Launches Commercial GMP Workshop 503 at Zhejiang Site PharmaBlock
21-Feb-2025 Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025 ABIVAX
21-Feb-2025 Evolva Holding SA publishes IFRS annual report 2024 Evolva Holding SA
20-Feb-2025 Boehringer Ingelheim and partners start clinical development of a first-in-class, inhaled gene therapy for people with cystic fibrosis Boehringer Ingelheim
20-Feb-2025 Qureight core imaging platform deployed within Vicore Phase 2b ASPIRE study of buloxibutid for IPF Qureight
20-Feb-2025 Mainz Biomed Expands into Switzerland with labor team w Mainz BioMed N.V.
20-Feb-2025 Immunic’s Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing Immunic AG